Investor Overview

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Recent News

Natera Reports Second Quarter 2019 Financial Results  -  8/7/2019
SAN CARLOS, Calif. , Aug. 7, 2019 /PRNewswire/ -- Natera, Inc.  (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for its second quarter ended June 30, 2019 and provided an update on recent business progress. More »
Publication Demonstrates Unique Ability of Panorama Test to Determine Zygosity in Twin Pregnancies  -  8/5/2019
100% Accuracy in Detecting Zygosity Enables Earlier Risk Stratification for Serious Perinatal Complications SAN CARLOS, Calif. , Aug. 5, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) , a global leader in cell-free DNA testing, today announced results of a prospective validation study published More »
Natera Announces Second Quarter 2019 Earnings Conference Call  -  7/31/2019
SAN CARLOS, Calif. , July 31, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2019 , after the market close on August 7, 2019 . More »
New ProActive™ Study From Natera Will Test for Rejection in 3,000 Kidney Transplant Recipients  -  6/24/2019
Study will evaluate improved clinical outcomes in patients using the Prospera™ dd-cfDNA test SAN CARLOS, Calif. , June 24, 2019 /PRNewswire/ --   Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a nationwide registry study for kidney transplant recipients More »
Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers  -  6/3/2019
Results Support Use of New Blood Test as Surrogate Endpoint in Clinical Trials Assessing Immune Checkpoint Inhibitor Effectiveness SAN CARLOS, Calif. , June 3, 2019 /PRNewswire/ -- A new study demonstrates the ability of Natera's Signatera™ test to assess patient response to immunotherapy in the More »

Upcoming Events

More events are coming soon.

Past events

Wednesday, 08/07/19 at 4:30 PM EDT

Footer disclaimer

Footer disclaimer

© Natera 2019. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.